Rheumatology Network: ACR Convergence 2022 Highlights

ACR 22 Convergence Preview, with Zsuzsanna McMahan, MD

“ACR Convergence 2022 will have a great deal to offer practicing rheumatologists, scientists, educators, rheumatology professionals, and trainees,” said Annual Meeting Planning Committee Chair Sharon L. Kolasinski, MD, FACR, a professor of clinical medicine at the University of Pennsylvania, in a statement from the ACR.

Rheumatology Patients Report High Levels of Satisfaction With Adalimumab Biosimilar

ABP 501 is an adalimumab biosimilar that was recently approved the European Medicines Agency.

Xenofon Baraliakos, MD: Efficacy and Safety of Bimekizumab in Non-Radiographic Axial Spondyloarthritis

ASAS40 responses increased between week 16 and week 52 in patients with non-radiographic axial spondyloarthritis and ankylosing spondylitis.

Examining Drivers of Cardiovascular Risk with Tofacitinib, with Deepak Bhatt, MD, MPH

Deepak Bhatt, MD, MPH, discusses a posthoc analysis of the ORAL Surveillance trial examining drivers of increased cardiovascular risk observed in the phase 3b/4 trial in patients with rheumatoid arthritis.

Allopurinol Use Linked to Lower Risk of First-Ever Coronary Event

Exposure to more than 100 mg was linked to significantly lower odds ratios for first-ever ACS event for women.